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Abstract
Converging clinical data suggest that peripheral inflammation is likely involved in the pathogenesis of the neuropsychiatric
symptoms associated with metabolic syndrome (MetS). However, the question arises as to whether the increased
prevalence of behavioral alterations in MetS is also associated with central inflammation, i.e. cytokine activation, in brain
areas particularly involved in controlling behavior. To answer this question, we measured in a mouse model of MetS, namely
the diabetic and obese db/db mice, and in their healthy db/+ littermates emotional behaviors and memory performances, as
well as plasma levels and brain expression (hippocampus; hypothalamus) of inflammatory cytokines. Our results shows that
db/db mice displayed increased anxiety-like behaviors in the open-field and the elevated plus-maze (i.e. reduced percent of
time spent in anxiogenic areas of each device), but not depressive-like behaviors as assessed by immobility time in the
forced swim and tail suspension tests. Moreover, db/db mice displayed impaired spatial recognition memory (hippocampus-
dependent task), but unaltered object recognition memory (hippocampus-independent task). In agreement with the well-
established role of the hippocampus in anxiety-like behavior and spatial memory, behavioral alterations of db/db mice were
associated with increased inflammatory cytokines (interleukin-1b, tumor necrosis factor-a and interleukin-6) and reduced
expression of brain-derived neurotrophic factor (BDNF) in the hippocampus but not the hypothalamus. These results
strongly point to interactions between cytokines and central processes involving the hippocampus as important
contributing factor to the behavioral alterations of db/db mice. These findings may prove valuable for introducing novel
approaches to treat neuropsychiatric complications associated with MetS.
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Introduction
For several decades, the prevalence of the metabolic syndrome
(MetS) and related comorbidities continuously increases world-
wide at alarming rate. This syndrome is defined as a constellation
of interrelated metabolic dysregulations, including abdominal
obesity, hypertension, hyperglycemia, insulin-resistance, leptin-
resistance and hypercortisolemia [1–3].
Mounting evidence highlights that patients with MetS often
experience a higher prevalence of mood symptoms and cognitive
dysfunctions than the general age-matched population [4–6]. The
overwhelming influence of metabolic and neuropsychiatric
disorders considerably impairs the quality of life of MetS patients
and results in incremental costs to health care systems around the
world [7]. Actually, neuropsychiatric symptoms emerge as
significant risk factors for aggravation of MetS and related health
outcomes, particularly cardiovascular diseases and type 2 diabetes
(T2D) [8–12]. Even so, relatively little is known about the
pathophysiological mechanisms contributing to the development
of neuropsychiatric symptoms in the context of MetS. Recent
evidence suggests that some major biological systems, including
the inflammatory system, may participate in both MetS and
neuropsychiatric disorders [13–15].
Inflammation is a key component of MetS, as elevated
circulating levels of inflammatory mediators facilitate the devel-
opment of this condition [16,17]. Severe obesity is associated with
an inflammatory profile characterized by increased plasma
production of cytokines and resulting in an imbalance of the
cytokine network [18]. Similarly, T2D is associated with a shift of
the balance between proinflammatory and anti-inflammatory
cytokines toward inflammation [19]. Consequently, MetS is
presently viewed not only as a metabolic disorder, but also as an
inflammatory disease affecting both innate and acquired immune
systems [17,20].
Abundant evidence supports immune-to-brain communication,
with peripheral cytokines acting on the brain to induce local
production of cytokines and to influence pathways involved in the
regulation of mood and cognition, including neurotransmitter
metabolism, neuroendocrine function and neural plasticity
[21,22]. Interestingly, we and others have identified peripheral
and central inflammatory factors as important mediators of the
neuropsychiatric symptoms observed in many medical illnesses
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[22–26]. We have found in mice that the selective activation of
enzymatic pathways involved in brain monoamine metabolism by
interferon-c (IFN-c) and tumor necrosis factor-a (TNF-a) mediates
development of depressive-like behaviors in response to chronic
infection [24–26]. The same mechanisms likely contribute to the
high incidence of depressive disorders reported in medically ill
patients chronically treated with IFN-a [27] or in elderly subjects
exhibiting systemic low-grade inflammation as manifested by
increased serum levels of C-reactive protein (CRP) and interleu-
kin-6 (IL-6) [28]. Besides, converging animal [29–31] and clinical
findings [32–34] support a main role for IL-6 in mood disorders
and cognitive decline. Mounting evidence suggests that systemic
inflammation, particularly higher peripheral IL-6, is associated
with brain inflammation [35,36] that might adversely affect mood,
learning and memory through processes related to neurodegen-
eration and structural remodeling [37–39]. These processes
mainly affect the hippocampus [40–42], a key brain area for
memory formation and mood [43,44].
A sizeable number of molecules are well-known to influence
hippocampal synaptic plasticity contributing to mood and memory
processes, but the brain-derived neurotrophic factor (BDNF) is a
major candidate in the context of MetS. BDNF has been found
critical in a number of memory tasks [45] and represents an
essential constituent of central neural circuits involved in
regulating energy homeostasis [46]. Intact hippocampal BDNF
signaling determines antidepressant efficacy and influences
anxiety-like behaviors [47]. Moreover, hippocampal BDNF
mRNA expression and signal transduction are negatively regulat-
ed by proinflammatory cytokines [48–50], with reported conse-
quences on cytokine-induced behavioral alterations [21,48,49].
There are but few reports concerned with the role of
inflammation in the onset of neuropsychiatric symptoms in
patients with MetS and/or obesity. Increased brain levels of
TNF-a and IL-6 induced by consumption of high-fat diet in mice
are associated with reduced BDNF levels and cognitive perfor-
mances [51]. At the clinical levels, cognitive impairments have
been recently reported to be more likely associated with MetS in
the presence of elevated circulating levels of CRP [11,52]. Other
clinical reports point to elevated circulating levels of IL-6 as
important determinant of mood symptoms [53,54] and cognitive
decline [32] associated with MetS and/or obesity. In light of the
present knowledge on the neurobiological and behavioral
consequences of elevated IL-6 concentrations, these data strongly
suggest that brain inflammation is likely involved in the
pathogenesis of the neuropsychiatric symptoms associated with
MetS. However, clinical studies in patients with MetS only assess
systemic inflammation and it is still unknown if enhanced cytokine
production associated with neuropsychiatric disorders in MetS
does exist in brain areas involved in controlling behavior,
particularly the hippocampus. In this context, corollary questions
arise as to whether all neuropsychiatric symptoms are equally
affected in MetS and which inflammatory pathways are potentially
activated in the hippocampus.
In the present study, we sought to answer these questions in a
mouse model of MetS, the db/db mice, which display T2D,
obesity, hyperglycemia, insulin-resistance and hyperinsulinemia as
a consequence of an inactivating mutation in the leptin receptor
[55]. There are but few reports showing that db/db mice also
display immune changes, particularly altered immune response to
infection both in terms of cytokine production [56,57] and sickness
behavior [58]. Few studies have dealt with the emotional
behaviors and cognitive performances of db/db mice [59–62],
but there are as yet no report regarding the potential involvement
of inflammatory processes, particularly within the brain, in
impaired emotional and cognitive behaviors. Therefore, the
present set of experiments was carried out to identify in db/db
mice potential alterations in depressive-like, anxiety-like and
cognitive behaviors together with a detailed assessment of their
peripheral and central inflammatory status. According to the role
of the hippocampus in emotional and cognitive behaviors [43,44]
we hypothesized that the behavioral deficits of db/db mice would
be specifically associated with activation of cytokine pathways in
the hippocampus.
Results
1–db/db mice display expected metabolic dysregulations
In accordance with their expected phenotype, db/db mice
were markedly heavier than db/+ controls (weight (g): 25.560.3
vs. 40.561 . 0a t1 0w e e k - o l d ;F (1,26)=220.0, p,0.0001), ate
more (daily food intake (g): 4.560.2 vs. 7.860.5 during the last
week before sacrifice; F(1,25)=43.6, p,0.0001) and showed a
marked increase in the proportion of adipose tissue compared
to db/+ mice (data not shown). This was associated with
hyperleptinemia (F(1,10)=266.2, p,0.0001), hyperinsulinemia
(F(1,10)=21.1, p,0.001), hyperglycemia (F(1,8)=14.3, p,0.005)
and hypercortisolemia (F(1,10)=11.4, p,0.01), but reduced
plasma concentrations of resistin (F(1,10)=13.4, p,0.005)
(Table 1).
2–db/db mice display increased anxiety-like behaviors
and impaired spatial working memory performances
Anxiety-like behaviors were assessed in the open-field (OF) and
elevated plus maze (EPM). When exposed to the OF, db/db mice
clearly spent less time (F(1,19)=4.9,p,0.05) and visited less often
(F(1,19)=13.5, p,0.005) the central area than db/+ mice (Fig. 1A).
The detailed time-course analysis of the number of entries
performed in this anxiogenic central area revealed a progressive
over-time increase in db/+ mice (time: F(1,110)=4.4, p,0.0001)
whereas central entries remained very few in db/db mice
throughout the test. Similarly, although all mice equally visited
the closed arms of the EPM, db/db mice displayed less entries
(F(1,20)=4.5,p,0.05; Fig. 1B) and reduced percent of time spent
into the open arms than db/+ mice (F(1,20)=6.48, p,0.05;
Fig. 1C). Moreover, these behavioral differences were not due to
Table 1. Concentrations of metabolic hormones and
cytokines in the plasma of db/+ and db/db mice.
Plasma db/+ db/db
Leptin (ng/ml) 2.860.7 63.763.7***
Resistin (ng/ml) 3.460.1 1.760.1**
Insulin (ng/ml) 1.160.2 5.961.0***
Glucose (mg/dl) 220.2614.7 632.86135.5**
Corticosterone (ng/ml) 26.266.1 148.2638.61**
IL-1b (pg/ml) 17.469.6 29.0611.5
TNF-a (pg/ml) 8.761.1 13.965.1
IL-6 (pg/ml) 11.765.3 136.7659.9*
MCP-1 (pg/ml) 36.869.2 80.6611.9*
Data represent means 6 SEM (n=6–7/group).
*p,.05,
**p,.01,
***p,.001 for db/db vs. db/+ mice.
doi:10.1371/journal.pone.0024325.t001
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more entries into the peripheral squares of the OF than db/+
mice (63.37% vs. 55.89%; F(1,19)=8.7,p,0.01) and both groups
exhibited similar number of total arm entries in the EPM (data
not shown). Thus, results obtained from the OF and EPM
paradigms converge to demonstrate greater anxiety-like behav-
iors in db/db mice compared to their db/+ counterparts. In
contrast, assessment of depressive-like behaviors in the tail
suspension test (TST) and forced swim test (FST) reveals similar
duration of immobility in both genotypes, suggesting that db/db
mice did not display greater depressive-like behavior than db/+
mice (Fig. 2).
We also measured spatial working memory performances of
db/db and db/+ mice using a spatial recognition test designed as a
hippocampus-dependent task [63,64]. During the pre-test session
of free exploration of two arms out of three in the Y-maze, the
number of visits and the time spent in each open arm were
similar in both genotypes indicating unaltered spontaneous
alternation (data not shown). Spatial memory performances
differed across the genotypes when a 30-min retention interval
was used, as revealed by main effects of genotype (F(1,18)=5.6,
p,0.05) and arm (F(1,18)=7.6,p,0.05) (Fig. 3A). Further analysis
indicated that db/+ mice spent more time exploring the novel
arm than the familiar arm (p,0.05), whereas db/db mice
randomly explored the different arms. Consequently, the index
of discrimination calculated as the time spent exploring the novel
arm divided by the total time exploring the different arms
multiplied by 100, was significantly higher than chance level in
db/+ mice (59%, one sample t-test: p,0.05), but not in db/db
mice (55%, p.0.05) (data not shown). When tested with a short
2-min ITI that corresponds to a minimal mnemonic demand,
both db/db and db/+ mice preferentially explored the novel arm
compared to familiar arms (F(1,46)=10.2, p,0.005; 62% and
60% for db/db and db/+ mice, respectively p,0.05) (data not
shown). In summary, db/db mice displayed normal spatial
recognition performances with a short retention interval, but
impaired performances once the mnemonic demand increased
together with the ITI. These data likely reflect a deficit in
hippocampus-dependent working memory rather than motor or
motivational disturbances.
To evaluate whether working memory performances were also
affected in a non-spatial task, mice were submitted to the novel
object recognition (NOR) task used as a hippocampus-indepen-
dent task [64,65]. After 30-min retention, all mice explored more
the novel object than the familiar one (F(1,36)=22.5, p,0.0001)
(Fig. 3B), although db/db mice spent globally less time exploring
the objects than db/+ mice (genotype: F(1,36)=12.7, p,0.005;
object 6 genotype: F(1,36)=4.4, p,0.05). Both db/+ and db/db
mice were therefore able to discriminate the novel object from the
familiar one, as confirmed by the fact that the index of
discrimination was statistically different from chance level (50%)
whatever the genotype (70.9% and 68.3% respectively; p,0.001).
To evaluate whether longer ITI could reveal an impairment of
object recognition in db/db mice, other mice were tested with a 1-h
ITI. Neither db/db nor db/+ mice preferentially explored the novel
object over the familiar one with a 1-h ITI, although db/+ mice
still spent more time exploring the objects than db/db mice
(genotype: F(1,34)=15.4, p,0.001) (data not shown). In summary,
db/db mice displayed selective behavioral alterations affecting
anxiety-like behavior and spatial working memory.
Figure 1. Anxiety-like behaviors of db/db and db/+ mice. (A) Percent of time spent in the center area of the open-field and temporal evolution
of the number of entries into this area. (B) Number of entries and (C) percent of time spent into the open arms of the elevated plus-maze. Data
represent means 6 SEM (n=6/group). * p,.05, ** p,.01 for db/db vs. db/+ mice.
doi:10.1371/journal.pone.0024325.g001
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and brain inflammation in db/db mice
Table 1 shows peripheral levels of several well-known markers
of inflammation. db/db mice displayed significantly higher plasma
levels of IL-6 (F(1,10)=6.2, p,0.05) and the chemokine MCP-1
(F(1,12)=3.0, p,0.05) than db/+ mice. Plasma levels of IL-1b and
TNF-a were low and similar in both genotypes, whereas no IFN-c
was detected whatever the group.
Cytokine mRNA expression was measured in the hippocampus,
a key brain areas for the control of spatial memory and anxiety-
like behaviors [43,44]. Concomitantly, the hypothalamus was used
as a control structure involved in physiological homeostasis, but
not in the control of anxiety-like and cognitive behaviors [44,46].
IFN-c and MCP-1 mRNA expression levels were similar
regardless the genotype and the area. Hippocampus mRNA
expression of IL-1b (F(1,9)=6.8, p,0.05), TNF-a (F(1,10)=7.4,
p,0.05) and IL-6 (F(1,8)=7.1, p,0.05) was significantly higher in
db/db mice than in their db/+ counterparts (Fig. 4A). In contrast,
hypothalamus TNF-a and IL-6 mRNA expression was similar in
both genotypes whereas db/db mice displayed lower levels of IL-1b
mRNA expression than db/+ mice (F(1,9)=7.6, p,0.05; Fig. 4B).
To further understand the functional consequences of increased
expression of cytokines, we next measured mRNA expression of
one of the key element of the IL-6 receptor complex, the
glycoprotein 130 (GP130), IL-6 being the only cytokine increased
at the periphery and in the hippocampus of db/db mice.
Additionally, we measured the mRNA expression of cytokine
signaling-3 (SOCS3), a classical indicator of cytokine signaling
pathway activation [66]. GP130 mRNA expression was stable
across the brain area and the genotype (Fig. 5A, 5C). On the
contrary, db/db mice displayed increased levels of SOCS3 mRNA
expression in the hippocampus (F(1,9)=6.7, p,0.05; Fig. 5A),
together with a reduced expression in the hypothalamus
(F(1,9)=12.1, p,0.01; Fig. 5C). Alterations displayed by db/db
mice in anxiety-like behaviors and spatial working memory were
therefore associated with hippocampal, but not hypothalamic,
low-grade inflammation.
Finally, we measured the mRNA expression of BDNF, a potent
neuroprotective growth factor regulated by cytokines [48–50] and
well-known to participate in mood regulation and memory
function [45,47]. BDNF was significantly reduced in the
hippocampus of db/db mice compared to db/+ mice (F(1,9)=7.8,
p,0.05; Fig. 5B), whereas no significant differences were observed
between both groups in the hypothalamus (Fig. 5D).
Discussion
Our study allows for the first time to directly relate in db/db
mice increased anxiety-like behaviors and impaired spatial
memory performances with activation of specific inflammatory
pathways within the hippocampus, a key brain area for the control
of emotional and cognitive behaviors.
Figure 2. Depressive-like behaviors of db/db and db/+ mice. Immobility time in the (A) tail suspension test and (B) forced swim test. Data
represent means 6 SEM (n=7/group).
doi:10.1371/journal.pone.0024325.g002
Figure 3. Working memory performances of db/db and db/+ mice. (A) Spatial recognition in the Y-maze expressed as the time spent
exploring the novel and the familiar arms. (B) Time spent exploring the novel and the familiar object in the novel object recognition task. In both
tasks, measures were assessed over a 5-min test and after 30-min retention. Data represent means 6 SEM (n=7–10/group). * p,.05, ** p,.01 for db/
db vs. db/+ mice.
doi:10.1371/journal.pone.0024325.g003
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the levels of (A) hippocampal and (B) hypothalamic IL-1b, TNF-a, IL-6, IFN-c and MCP-1 mRNA expression, as calculated in relation to the averaged
value for control saline group. IL-1b, interleukin-1b; TNF-a, tumor necrosis factor-a; IFN-c, interferon-c; MCP-1, monocyte chemotactic protein-1. Data
represent means 6 SEM (n=6/group). * p,.05 for db/db vs. db/+ mice.
doi:10.1371/journal.pone.0024325.g004
Figure 5. mRNA expression levels of GP130, SOCS3 and BDNF in the hippocampus and hypothalamus. Relative fold changes in the
levels of (A–B) hippocampal and (C–D) hypothalamic GP130, SOCS3 and BDNF mRNA expression, as calculated in relation to the averaged value for
control saline group. GP130, glycoprotein 130; SOCS3, suppressor of cytokine signaling-3; BDNF, brain-derived neurotrophic factor. Data represent
means 6 SEM (n=6/group). * p,.05 for db/db vs. db/+ mice.
doi:10.1371/journal.pone.0024325.g005
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mood disorders report a positive association [6,10,15]. Although
measuring mood in rodents could appear limiting, the develop-
ment of consistent and reliable behavioral tests modeling different
core symptoms of anxiety and depression rather than the entire
syndromes has provided very useful tools to study their respective
pathophysiology [67]. Here, data obtained in different experi-
mental paradigms converge to indicate that db/db mice display
increased anxiety-like behaviors, as previously suggested [62], but
not depressive-like behaviors. Increased immobility in the FST has
been reported in leptin-deficient (ob/ob) mice when experimental
conditions much more stressful than ours are used (longer
exposure to the FST and for 3 consecutive days) [68]. Of note,
depressive-like behaviors in the FST and/or TST mostly increase
under challenging conditions such as stress exposure [69] or
immune stimulation [24–26,70]. The possibility that db/db mice
would display greater depressive-like behaviors in such conditions
is currently under study. While this may be, the current study
clearly shows that db/db mice displayed increased anxiety-like, but
not depressive-like, behaviors in basal conditions.
Clinical studies have reported that MetS adversely impairs
cognition, although not all cognitive domains are equally affected
[4,5,11]. Our study further extends these findings by demonstrat-
ing task-specific cognitive impairments in db/db mice using two
working memory paradigms (the Y-maze and NOR). After
30 minutes of retention, db/db mice exhibited spatial working
memory impairment in the Y-maze while their performances were
unaltered in NOR memory task. Moreover, the spatial deficit in
db/db mice is not due to motor and/or motivational problems as
their spatial performance was intact with a shorter retention
interval (2-min). Intact performances of db/db mice in the NOR
task disagree with recently published data showing NOR
impairment in these mice with the same 30-min ITI [61].
However, two important differences between their experimental
protocol and ours can likely explain this apparent discrepancy.
First, they used C57BL/6J mice as controls instead of db/+ mice
(as we used), which have similar genetic background (C57BL/
6J6DBA/2J) and perinatal environment as their littermates db/db
mice. Interestingly, we recently showed differences in the duration
of object exploration between C57BL/6J and db/+ mice (data not
shown) that can likely be explained by their different genetic
background and/or different perinatal environment. Second and
more importantly, they exposed db/db mice only once to the
testing cage before the NOR training and test, whereas in our
protocol mice were extensively habituated to the testing cage
(15 min per day during 8 days). According to the fact that the level
of habituation to the experimental context influences the
emotional arousal and performances during NOR [71,72] and
that db/db mice show greater anxiety-like behaviors than controls,
it is likely that testing db/db mice in higher stressful conditions than
ours may interfere with their NOR performances.
In parallel to behavioral alterations, we report neurobiological
changes in db/db mice affecting molecules well-known to
participate in emotional and cognitive behaviors, particularly
cytokines [21,22]. Expression level of IL-6, TNFa and IL-1b
mRNAs was selectively increased by ,80% in the hippocampus,
but not the hypothalamus, of db/db mice. Although we only
measured cytokine transcripts, these changes are likely to be
reflected in changes of protein levels contributing to downstream
neurobiological and behavioral modulations [73]. This assumption
is supported by the concomitant increase of hippocampal SOCS3
mRNA expression that is classically used as an indicator of
cytokine signaling pathway activation, mainly IL-6 [66]. In
contrast, IL-1b mRNA expression is significantly reduced in the
hypothalamus of db/db mice. This can be linked to the increased
food intake of these mice as mounting evidence indicates the
anorectic effect of enhanced hypothalamic expression of IL-1
[21,74], including in response to leptin [75]. Of note, this result is
particularly relevant to better understand the role of brain
cytokines in the impairment of food intake in db/db mice, although
this question has not been directly addressed in the present study.
As reported for cytokines, BNDF is also well-known to contribute
to mood regulation and memory function, particularly in the
hippocampus [45,47] where its expression is negatively regulated
by cytokines [48,49]. Accordingly, the increase of proinflamma-
tory cytokine expression we found in the hippocampus of db/db
mice is accompanied by ,60% decrease of hippocampal, but not
hypothalamic, BDNF mRNA expression. This change is likely
reflected in changes of functional protein levels since significant
correlations have been reported between both BDNF mRNA
expression and protein levels [76,77].
These neurobiological changes are observed in the hippocam-
pus, but not in the hypothalamus. This is particularly relevant in
light of the behavioral alterations of db/db mice. Indeed, we found
that db/db mice are impaired in spatial, but not in object,
recognition tasks for a similar delay and considerable literature
shows that spatial memory, but not object memory, requires
normal hippocampal functioning [65,78]. This interpretation
agrees with data reporting that db/db mice are impaired in the
hidden-platform version of the Morris water-maze test (a
hippocampus-dependent situation), but not under visible-platform
conditions (a hippocampus-independent situation) [59–61]. More-
over, the hippocampus is also involved in anxiety-related
behaviors [43]. Therefore the higher level of anxiety-like behaviors
we found in db/db mice (see also Stranahan et al. [62]) could also
be linked to the neurobiological changes we found in the
hippocampus of these mice, although further studies are needed
to measure potential neurobiological changes in other brain areas
well-known to participate in controlling emotional behavior,
particularly the amygdala complex (for instance see [79]).
All these data support a key role for the hippocampal changes
(increased cytokines, decreased BDNF) in the cognitive and
emotional alterations displayed by db/db mice. Interestingly,
chronic overexpression of brain IL-6 or hippocampal IL-1b in
transgenic mice impairs learning [37,41]. These findings concur
with several reports highlighting the relationship between
neuroinflammation, alterations of hippocampal synaptic plasticity
and impaired cognitive performances [38,39,51]. Interestingly,
different animal studies report that increased levels of hippocam-
pal IL-6 interfere with local long-term potentiation, neurogenesis
and synaptic plasticity [40–42], whereas blocking hippocampal IL-
6 intracellular pathway prevents cytokine-induced alterations of
synaptic activity and spatial learning [80]. In humans, circulating
IL-6 concentrations have been shown to covary inversely with
hippocampal grey matter volume [36] and cognitive performances
[32]. Chronic proinflammatory cytokines have also been shown to
produce detrimental effects on mood [22–26]. Consistent clinical
data report a significant correlation between elevated circulating
levels of inflammatory markers, particularly IL-6, and develop-
ment of anxiety symptoms [33,81], including in obese patients
[53,54]. Likewise, experimental studies using IL-6-deficient mice
[30] or rats bred for extremes in anxiety-related behavior [82]
support a role of IL-6 in anxiety-like behavior. Concerning BDNF,
decreased level in the hippocampus is associated with impaired
synaptic plasticity, cognitive performances [45] and mood-related
behaviors [47]. Interestingly, IL-1b modulates memory-induced
increase in hippocampal BDNF mRNA expression and signal
transduction [21,48,50]. Accordingly, elevated cytokine levels
Neuroinflammation Parallels Behavioral Deficits
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decrease BDNF level and consequently to impair anxiety-like
behaviors and spatial cognitive performances.
Beyond elevated cytokine levels and related neurobiological
changes, db/db mice also displayed elevated plasma levels of leptin,
insulin and corticosterone. In addition to their metabolic
properties, leptin and insulin can modulate behavior by acting
within the brain [83,84]. Consequently, impaired leptin and/or
insulin signaling activation, as observed in db/db mice, has been
proposed as potential link between behavioral and metabolic
disorders. Although this assumption cannot be totally excluded
based on the present data, several lines of evidence suggest that
leptin does not play a main role in mediating behavioral
alterations of db/db mice. Indeed, cognitive impairment displayed
by db/db mice can be improved by normalization of corticosterone
levels, without restoring impaired leptin signaling pathway [61,62].
Moreover, caloric restriction and running enhance exploratory
behavior in db/db mice, without changing serum leptin levels [62].
Similarly, insulin unlikely contributes to the behavioral alterations
reported in db/db mice. Indeed, brain concentrations of glucose
and insulin are similar in both db/db and db/+ mice and remained
unchanged after normalization of peripheral hyperinsulinemia
[61]. Moreover, caloric restriction and running completely
reversed hyperglycemia in db/db mice, without reducing anxiety-
like behavior in the open-field [62]. Likewise, normalizing
hyperglycemia in insulin-deficient rats does not reverse spatial
cognitive impairment [85]. These data match those showing that
the increased risk of cognitive dysfunction reported in MetS
patients is independent from the presence of diabetes [4].
Additionally, it was recently suggested that elevated corticosterone
contributes to cognitive alterations in db/db mice by acting within
the hippocampus [61]. Normalizing plasma corticosterone levels
reverses alterations of hippocampal plasticity and improves
hippocampus-dependent memory [61]. However, these findings
do not preclude the involvement of other factors, namely
proinflammatory cytokines, in cognitive and emotional alterations.
As both the inflammatory system and the hypothalamic-pituitary-
adrenal axis have been found tightly interrelated [86], it would be
of interest to assess in db/db mice whether normalizing plasma
corticosterone also normalizes hippocampal proinflammatory
cytokines. Additionally, this study should be broadened to other
brain areas, particularly the amygdala complex, since 1) it plays a
key role in controlling emotional behavior, particularly anxiety
[79] and 2) it can be targeted by both corticosterone and cytokines
[87]. Based on all these converging data, it can reasonably be
proposed that the behavioral profile displayed by db/db mice likely
results from the concerted interactions of cytokines and glucocor-
ticoids with central processes involving the hippocampus and
controlling cognition and emotionality.
In conclusion, although only correlative and with the limitation
inherent to the measurement of neurobehavioral reactivity in
rodents, the present results strongly point to hippocampal
inflammation as important contributing factors to the pathophys-
iology of neuropsychiatric complications associated with MetS.
These findings may prove valuable for introducing novel
approaches to treatment, alongside currently used non-pharma-
cologic and pharmacologic interventions.
Materials and Methods
Animals
All animal experiments were conducted according to the INRA
Quality Reference System, and to relevant French (Directive 87/
148, Ministe `re de l’Agriculture et de la Pe ˆche) and international
(Directive 86/609, November 24
th 1986, European Community)
legislation. They adhered to protocols approved by Re ´gion
Aquitaine Veterinary Services (Direction De ´partementale de la
Protection des Animaux, approval ID: A33-063-920). Every effort
was made to minimize suffering and the number of animal used.
Male db/db (C57BLKS/J-lepr
db/lepr
db; n=40) and db/+
(C57BLKS/J-lepr
db/+;n= 4 0 ) mice obtained from Charles River
Laboratories (France) were housed individually under a normal
12-hour light:dark cycle with food and water available ad libitum.
Mice were handled daily for 1 week before the experiment onset to
minimize stress reactions to manipulation. They were 8 to 10
weeks-old at the time of behavioral assessments.
Behavioral measurements
Experiments were performed in the morning under conditions
of dim light and low noise. Behavior was videotaped and scored
using ‘‘The Observer Basic’’ software (Noldus, Netherlands). Each
mouse was submitted to a maximum of two different behavioral
tests, with a 1-week interval between tests. All testing equipment
was thoroughly cleaned between each session.
Open-field (OF). Mice were exposed to an unknown square
area (40640 cm) from which escape is prevented by surrounding
walls (16 cm high). The apparatus was virtually divided into 4
central squares defined as the central area and 12 squares along
the walls that are defined as the periphery. Each mouse was placed
in the central area and allowed to freely explore the OF for
10 min. Parameters recorded to evaluate anxiety-like behavior
were the number of entries and the percent of time spent in the
central area [88].
Elevated Plus Maze (EPM). The EPM was a plus shaped
acryl maze with two opposing open arms (3068 cm) and two
opposing closed arms (3068615 cm) connected by a central
platform (868 cm) and elevated 120 cm above the floor. Each
mouse was placed in the center of the maze facing an open arm
and the number of arm entries, as well as the percent of time spent
in open arms, was assessed during a 5-min period. An entry was
scored as such only when the mouse placed all four limbs into any
given arm. A reduction of the percent of time spent and number of
entries into the open arms is considered as an anxiety-like index,
independent of locomotor activity [88].
Tail Suspension Test (TST). This standardized test of
depressive-like behavior was carried out as previously described
[24,70]. Briefly, an adhesive tape was fixed to the mouse tail and
hooked to a horizontal ring stand bar placed 30 cm above the
floor. The test was conducted for a 6-min period in a visually
isolated area. Mice demonstrated several escape attempts
interspersed with immobility periods during which they hung
passively and completely motionless. Depressive-like behavior was
inferred from increased duration of immobility.
Forced Swim Test (FST). This standardized test of
depressive-like behavior was essentially conducted as previously
described [24,70]. Briefly, each mouse was placed individually in a
cylinder (16631 cm) containing warm water (2561uC) to avoid
temperature-related stress response. Mice were tested during a 6-
min period. Immobility time was determined by the time a mouse
stopped struggling and moved only slowly to remain floating in the
water, keeping its head above water. Increased duration of
immobility has been proposed to reflect a state of helplessness that
is reduced by antidepressants.
Y-maze. Spontaneous spatial recognition in the Y-maze was
used as a hippocampal-dependent test as previously described
[63,64]. The apparatus was a Y-shaped acryl maze with three
identical arms (3468614 cm). Corncob litter covered the floor
and was mixed between each trial in order to remove olfactory
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constant during the whole test. Discrimination of novelty versus
familiarity was based on the different aspects of the environment
that the mouse can perceive from each arm of the Y-maze. In the
first trial of the test (acquisition), one arm was closed with a door
and mice were allowed to freely visit the two other arms for 5 min.
After a 30-min inter-trial interval (ITI), mice were again placed in
the start arm for the second trial (retrieval) and allowed free access
to all three arms for 5 min. Start and closed arms were randomly
assigned to each mouse. Arm entries were defined as all four paws
entering the arm. Preference for novelty was also measured using a
short 2-min ITI between acquisition and retrieval in order to
control for potential motivational disturbances [63,64]. Analyses
were based on the time spent exploring the novel and the familiar
arms during the second trial. An index of discrimination between
novel and familiar arms was calculated as the ratio of the [time
spent in the novel arm/(time spent in the novel + adjacent
arms)]6100. An index of discrimination significantly higher than
chance level (50%) indicates therefore that mice indeed recognize
the novel arm.
Novel object recognition (NOR). This task is a free
exploration paradigm allowing mice to explore objects in a non-
threatening and familiar environment. It was used as a
hippocampal-independent task [64,65]. Mice were first
acclimatized in an opaque acryl cage (43628619 cm) for
15 min per day during the week before training. The floor was
covered with corncob litter that was mixed between each trial in
order to remove olfactory cues. On the ninth day, mice were
placed in the experimental cage with two identical objects during a
10-min training session. Three sets of objects with different shapes
and colors were used for discrimination. Each object was chosen
on the basis of a preliminary study examining the preferences of a
separate group of mice (data not shown) and was heavy enough
not to be displaced by a mouse. After a 30-min or 1-hour ITI, one
of the familiar objects was replaced by a novel object, with a
different shape and color, to test for memory retention. During the
5-min test, exploration of each object was defined as sniffing or
touching the object with the nose and/or forepaws. Analyses were
based on the time spent exploring the novel and the familiar
objects. An index of discrimination was calculated as the ratio of
the [time spent exploring the novel object/(total time spent
exploring both objects)]6100.
Biochemical measurements
After completion of the behavioral experiments, some db/db and
db/+ mice were euthanized by CO2 inhalation (10–12 weeks-old at
the time of sacrifice). Blood samples were immediately collected
via cardiac puncture into EDTA (10%)-coated chilled tubes. After
centrifugation (10 min, 3000 g,4 uC), aliquots of plasma were
stored at 280uC. Mice were perfused with chilled PBS via the
ascending aorta to remove all traces of blood from tissues. Brains
were rapidly extracted from the skulls and carefully dissected. The
hippocampus and the hypothalamus were immediately collected,
dried frozen and stored until assaying.
Hormones and cytokines assay. As previously described
[24,35], plasma leptin, insulin, resistin, monocyte chemotactic
protein-1 (MCP-1), IL-1b, IL-6, TNF-a and IFN-c were measured
with the mouse adipokine and cytokine LINCOplex kits
(Linco Research, Inc., St. Charles, MO, USA) following the
manufacturer’s instructions. Plasma corticosterone concentrations
were measured using a commercial RIA Kit (Diasorin, Antony,
France). Plasma glucose levels were measured using a One Touch
Ultra glucometer per the manufacturer’s instructions. All samples
were run in duplicate.
Reverse transcription and real-time RT-PCR. Total
RNA was extracted from the hippocampus and hypothalamus
using a RNeasy Mini Kit (Qiagen) and reverse-transcribed as
previously described [25,26,35,64]. Real-time RT-PCR was
performed on an ABI Prism 7700 using Taqman gene expres-
sion assays for sequence-specific primers purchased from Applied
Biosytems (Foster City, CA). Reactions were performed in
duplicate according to manufacturer instructions as previously
described [25,26,35]. Relative expression levels were calculated
according to the methods of Livak and Schmittgen [89] and
plotted as fold change relative to the appropriate control
condition.
Statistical analysis
Results are presented as mean 6 SEM and were analyzed using
a one-way (genotype) or a two-way (genotype6arm; genotype6ob-
ject) ANOVA followed by a post-hoc pair wise multiple comparison
procedure using the Fischer’s LSD method, if the interaction was
significant.
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